Anti-cytokine targeted therapies for ANCA-associated vasculitis

To assess the benefits and harms of anti-cytokine targeted therapy for patients with ANCA-associated vasculitis in terms of the following primary outcomes: mortality, disease activity (remission, durable remission, disease relapse) and adverse events such as withdrawals due to adverse events, total adverse events and serious adverse events.

This is a protocol.